The Zhitong Finance App learned that recently, the global peptide and oligonucleotide (TIDES) field focused on disclosing a number of clinical developments, involving functional treatment of chronic hepatitis B, long-term weight management of obesity, metabolism-related steatohepatitis (MASH), and cardiovascular metabolic diseases. Many studies have entered phase 2b to phase 3.
Teng Shengbo Pharmaceutical (02137) announced the positive results of the phase 2b study of hepatitis B small interfering RNA (siRNA) therapy with elebsiran combined immunotherapy. Some patients maintained hepatitis B surface antigen (HBsAg) clearance 24 weeks after treatment was completed.
Ganli Pharmaceutical (603087.SH) announced the positive top-line results of the Phase 3b Gradual-3 study of the ongoing GLP-1 receptor agonist Bofanglutide (GZR18) to treat obese or overweight adults. The study reached the main end point, showing that reducing the frequency of administration of bofanglutide to once a month after early weight loss treatment was still effective in maintaining the achieved weight loss.
MSD (MRK.US) revealed the results of a phase 2b clinical study of the ongoing peptide therapy efinopegdutide (MK-6024) to treat MASH during the 2026 American Society for Hepatology Research Annual Meeting. The study reached the main end point. After 52 weeks of treatment, the proportion of patients in each efinopegdutide dose group who achieved MASH relief and liver fibrosis did not worsen was significantly higher than in the placebo group.
efinopegdutide is a GLP-1/glucagon dual receptor agonist injected subcutaneously once a week. The drug aims to regulate energy metabolism, reduce liver fat accumulation, and explore potential improvements in liver inflammation and fibrosis by simultaneously activating GLP-1 and glucagon receptors.
